Re-Irradiation for Locally Recurrent Lung Cancer: A Single Center Retrospective Analysis
Authors:
- Brane GrambozovBGBrane Grambozov
- Evelyn NussdorferENEvelyn Nussdorfer
- Julia KaiserJKJulia Kaiser
- Sabine GerumSGSabine Gerum
- Gerd FastnerGFGerd Fastner
- Markus StanaMSMarkus Stana
- Christoph GaisbergerCGChristoph Gaisberger
- Romana WassRWRomana Wass
- Michael StudnickaMSMichael Studnicka
- Felix SedlmayerFSFelix Sedlmayer
- Franz ZehentmayrFranz Zehentmayr
Open Access
- 13 May 2021
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 28 (3) , 1835-1846
Abstract
The treatment of locally recurrent lung cancer is a major challenge for radiation-oncologists, especially with data on high-dose reirradiation being limited to small retrospective studies. The aim of the present study is to assess overall survival (OS) for patients with locally recurrent lung cancer after high-dose thoracic reirradiation. Thirty-nine patients who were re-irradiated for lung cancer relapse between October 2013 and February 2019 were eligible for the current retrospective analysis. All patients were re-irradiated with curative intent for in-field tumor recurrence. The diagnostic work-up included a mandatory 18F-FDG-PET-CT scan and—if possible—histological verification. The ECOG was ≤2, and the interval between initial and second radiation was at least nine months. Thirty patients (77%) had non-small cell lung cancer (NSCLC), eight (20%) had small cell lung cancer (SCLC), and in one patient (3%) histological confirmation could not be obtained. More than half of the patients (20/39, 51%) received re-treatment with dose differentiated accelerated re-irradiation (DART) at a median interval of 20.5 months (range: 6–145.3 months) after the initial radiation course. A cumulative EQD2 of 131 Gy (range: 77–211 Gy) in a median PTV of 46 mL (range: 4–541 mL) was delivered. Patients with SCLC had a 3 mL larger median re-irradiation volume (48 mL, range: 9–541) compared to NSCLC patients (45 mL, range: 4–239). The median cumulative EQD2 delivered in SCLC patients was 84 Gy (range: 77–193 Gy), while NSCLC patients received a median cumulative EQD2 of 135 Gy (range: 98–211 Gy). The median OS was 18.4 months (range: 0.6–64 months), with tumor volume being the only predictor (p < 0.000; HR 1.007; 95%-CI: 1.003–1.012). In terms of toxicity, 17.9% acute and 2.6% late side effects were observed, with a toxicity grade >3 occurring in only one patient. Thoracic high dose reirradiation plays a significant role in prolonging survival, especially in patients with small tumor volume at recurrence.Keywords
This publication has 33 references indexed in Scilit:
- Provider decision regret—a useful method for analysis of palliative thoracic re-irradiation for lung cancer?Strahlentherapie und Onkologie, 2020
- Pulmonary function decreases moderately after accelerated high‐dose irradiation for stage III non‐small cell lung cancerThoracic Cancer, 2019
- Prognostic factors in stereotactic body radiotherapy of lung metastasesStrahlentherapie und Onkologie, 2018
- Re-irradiation for Locally Recurrent Lung Cancer: Evidence, Risks and BenefitsClinical Oncology, 2018
- High-dose, conventionally fractionated thoracic reirradiation for lung tumorsLung Cancer, 2014
- Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatmentRadiotherapy and Oncology, 2014
- Stereotactic Body Radiation Therapy for Patients With Lung Cancer Previously Treated With Thoracic RadiationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Is re-irradiation effective in symptomatic local recurrence of non small cell lung cancer patients? A single institution experience and review of the literature.2009
- Non-small-cell lung cancer: reirradiation for loco-regional relapse previously treated with radiation therapyInternational Journal of Clinical Oncology, 2005
- Tumor heterogeneity, tumor size, and radioresistanceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1989